The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer

Neutropenia is a dose‐related treatment‐limiting and costly adverse event of pemetrexed. We postulate that individualized dosing reduces the incidence of neutropenia. The aims of this study were (i) to investigate the costs of pemetrexed‐related neutropenia and (ii) to determine the pharmacoeconomic...

Descripción completa

Detalles Bibliográficos
Autores principales: de Rouw, Nikki, de Boer, Merel, Boosman, René J., van den Heuvel, Michel M., Burger, David M., Lieverse, Joris E., Derijks, Hieronymus J., Frederix, Geert W.J., ter Heine, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304220/
https://www.ncbi.nlm.nih.gov/pubmed/35048355
http://dx.doi.org/10.1002/cpt.2529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304220/
https://www.ncbi.nlm.nih.gov/pubmed/35048355
http://dx.doi.org/10.1002/cpt.2529

Ejemplares similares